Linked Life Data

18421311

Source:http://linkedlifedata.com/resource/pubmed/id/18421311

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2008-9-10
pubmed:abstractText
HER-2/neu transgene-modified dendritic cell (DC)-based vaccines are potent at eliciting HER-2/neu-specific antitumor immunity. In this study, we constructed a recombinant adenovirus (RGD)AdVneu with fiber gene modified by RGD insertion into the viral knob's H1 loop. We transfected DCs with (RGD)AdVneu, and assessed/compared HER-2/neu-specific humoral and cytotoxic T lymphocyte (CTL) responses and antitumor immunity derived from the original AdVneu-transfected DCs (DCneu1) and (RGD)AdVneu-transfected DCs (DCneu2). We demonstrated that DCneu2 displayed increased HER-2/neu expression by 8.3-fold compared to DCneu1. We also demonstrated that DCneu2 vaccination induced stronger HER-2/neu-specific humoral and CTL immune responses than DCneu1 vaccination. DCneu2 vaccination protected all the mice from HER-2/neu-expressing Tg1-1 tumor cell challenge in wild-type FVB/NJ mice, compared to a partial protection in DCneu1-immunized mice. In addition, DCneu2 vaccination also significantly delayed tumor growth than DCneu1 immunization (P<0.05) in Tg FVBneuN mice. Three immunizations of DCneu2 starting at the mouse age of 2 months also significantly delayed breast cancer development in Tg mice compared to DCneu2 vaccine (P<0.05). Importantly, DCneu2 vaccine reduced breast carcinogenesis by 9% in Tg mice with self HER-2/neu tolerance. Therefore, vaccination of fiber-modified adenovirus-transfected DCs to enhance expression of tumor antigens such as HER-2/neu is likely representative of a new direction in DC-based vaccine of breast cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1476-5500
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
655-66
pubmed:meshHeading
pubmed-meshheading:18421311-Adenoviridae, pubmed-meshheading:18421311-Animals, pubmed-meshheading:18421311-Antibody Formation, pubmed-meshheading:18421311-Cancer Vaccines, pubmed-meshheading:18421311-Cell Line, Tumor, pubmed-meshheading:18421311-Cell Proliferation, pubmed-meshheading:18421311-Dendritic Cells, pubmed-meshheading:18421311-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:18421311-Flow Cytometry, pubmed-meshheading:18421311-Genes, erbB-2, pubmed-meshheading:18421311-Genetic Vectors, pubmed-meshheading:18421311-Male, pubmed-meshheading:18421311-Mammary Neoplasms, Animal, pubmed-meshheading:18421311-Mice, pubmed-meshheading:18421311-Mice, Transgenic, pubmed-meshheading:18421311-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:18421311-T-Lymphocytes, Cytotoxic
pubmed:year
2008
pubmed:articleTitle
Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
pubmed:affiliation
Division of Oncology, Cancer Research Unit, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't